Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target

Lakefront Biotherapeutics is attractive because gamgertamig appears underappreciated, with >60 autoimmune-cytopenia patients showing rapid, deep B-cell depletion, durable responses, and very low CRS rates despite higher dosing, suggesting a differentiated profile versus CAR-T. Its outlook is further supported by a strong balance sheet, with €2B in cash expected by end-2026, an implied negative €180M EV at current levels, and an expectation to be cash flow positive by YE26 after the cell-therapy wind-down, which limits downside and preserves capital for development. The company also has meaningful long-term optionality from registrational studies set to begin in 2027, potential peak non-prob.-adjusted royalties up to $885M, and a favorable partnership structure with GILD that reduces risk while leaving room for additional BD or in-licensing.

Lakefront Biotherapeutics is viewed negatively because its investment case depends on successful pipeline execution and new-asset acquisition, yet the company faces meaningful uncertainty around whether it can secure competitive assets at attractive valuations. The limited quantitative data reported to date for gamgertamig, alongside the need to optimize dosing to balance CRS risk, cell depletion, and durability, heightens clinical and regulatory risk, while several BCMAxCD3 bispecifics in development could compress future opportunity and raise the bar for success. If GLPG3667 disappoints or is not out-licensed, and if early-stage compounds encounter unknown toxicity issues or weak differentiation, the company’s commercial prospects could remain constrained and shares could trade lower.